Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain
- PMID: 9268666
- DOI: 10.1006/jmbi.1997.1196
Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain
Abstract
The recombinant light chain (L chain) of an antibody raised by immunization with vasoactive intestinal polypeptide (VIP) cleaved this peptide on the C-terminal side of basic residues. The major sites of cleavage in VIP were two adjacent peptide bonds, Lys20-Lys21 and Lys21-Tyr22. Lower levels of cleavage were evident at Arg14-Lys15 and Lys15-Gln16. Hydrolysis of radiolabeled VIP by the L chain was inhibited by two serine protease inhibitors, diisopropylfluorophosphate and aprotinin, but not by soybean or lima bean trypsin inhibitors or inhibitors of other classes of proteases. To probe the role of the VH domain, single chain Fv constructs composed of the VL domain of the anti-VIP L chain linked via a 14-residue peptide to its natural VH domain partner or an irrelevant anti-lysozyme VH domain (hybrid Fv) were prepared. The anti-VIP Fv hydrolyzed VIP with Ks 21.4-fold lower than the L chain and 250-fold lower than the hybrid Fv, suggesting increased affinity for the substrate ground state due to the anti-VIP VH domain. The kinetic efficiency (kcat/Ks) of the anti-VIP Fv was 6.6-fold greater compared to the L chain and 29.4-fold greater compared to the hybrid Fv. Peptide-MCA substrates unrelated in sequence to VIP were hydrolyzed by the anti-VIP Fv and L chain at equivalent rates. These observations lead to a model of catalysis by the anti-VIP Fv in which the essential catalytic residues are located in the VL domain and additional residues from the VH domain are involved in high affinity binding of the substrate.
Similar articles
-
Site-directed mutagenesis of proteolytic antibody light chain.J Mol Biol. 1995 Nov 10;253(5):658-64. doi: 10.1006/jmbi.1995.0580. J Mol Biol. 1995. PMID: 7473741
-
Proteolytic activity of an antibody light chain.J Immunol. 1994 Dec 1;153(11):5121-6. J Immunol. 1994. PMID: 7963569
-
DNA binding by the VH domain of anti-Z-DNA antibody and its modulation by association of the VL domain.J Immunol. 1999 Apr 15;162(8):4663-70. J Immunol. 1999. PMID: 10202006
-
Medical applications of single-chain antibodies.Int Rev Immunol. 1993;10(2-3):195-217. doi: 10.3109/08830189309061696. Int Rev Immunol. 1993. PMID: 8360586 Review.
-
Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies.Ciba Found Symp. 1991;159:156-67; discussion 167-73. doi: 10.1002/9780470514108.ch11. Ciba Found Symp. 1991. PMID: 1720373 Review.
Cited by
-
Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies.Mol Biotechnol. 2007 Jun;36(2):113-22. doi: 10.1007/s12033-007-0003-7. Mol Biotechnol. 2007. PMID: 17914190
-
Antibodies as defensive enzymes.Springer Semin Immunopathol. 2005 Mar;26(4):485-503. doi: 10.1007/s00281-004-0191-1. Epub 2005 Jan 5. Springer Semin Immunopathol. 2005. PMID: 15633014 Review.
-
Beneficial catalytic immunity to abeta peptide.Rejuvenation Res. 2010 Apr-Jun;13(2-3):179-87. doi: 10.1089/rej.2009.0958. Rejuvenation Res. 2010. PMID: 20370602 Free PMC article. Review.
-
A human germ line antibody light chain with hydrolytic properties associated with multimerization status.J Biol Chem. 2009 Nov 27;284(48):33079-87. doi: 10.1074/jbc.M109.036087. Epub 2009 Oct 2. J Biol Chem. 2009. PMID: 19801545 Free PMC article.
-
Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.J Biol Chem. 2008 Dec 26;283(52):36724-33. doi: 10.1074/jbc.M806766200. Epub 2008 Oct 30. J Biol Chem. 2008. PMID: 18974093 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources